Literature DB >> 8358984

Free plasma concentrations of piroxicam in patients with osteoarthritis: relation to age, sex and efficacy.

O Hundal1, H E Rugstad.   

Abstract

Steady state piroxicam plasma samples from 85 patients suffering from osteoarthritis of the hip and/or the knee, and treated with piroxicam 20 mg daily for at least four weeks, were obtained. Twenty-seven of these patients had a newly diagnosed osteoarthritis and had not been treated with a nonsteroidal antiinflammatory drug (NSAID) previously. The plasma samples were subjected to equilibrium dialysis, analyzed by HPLC and total and free drug concentrations measured and unbound fractions were calculated. In the 27 newly diagnosed patients with free piroxicam concentrations ranging from 0.004 to 0.117 micrograms/ml, there was no correlation between free concentration and change in any of the clinical response variables from pretrial to week 4. In the total patient population free concentrations were 0.057 +/- 0.038 micrograms/ml (mean +/- standard deviation). Females had a 79% higher free concentration than males (p < 0.0002) and there was a statistically significant (p < 0.01) increase of free concentration with increasing age in females. The unbound fraction was 0.87% +/- 0.36% (mean +/- SD). There was no difference in unbound fraction between the sexes, nor could we detect any change with increasing age.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8358984     DOI: 10.1007/bf02231532

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

1.  Determination of free concentration of piroxicam and naproxen in plasma. The influence of experimental conditions in equilibrium dialysis.

Authors:  O Hundal; H E Rugstad
Journal:  Fundam Clin Pharmacol       Date:  1991       Impact factor: 2.748

2.  Penetration of naproxen and salicylate into inflammatory exudates in the rat.

Authors:  N S Doherty; M Anttila; P B Dean
Journal:  Ann Rheum Dis       Date:  1977-06       Impact factor: 19.103

3.  The determination of naproxen by spectrofluorometry and its binding to serum proteins.

Authors:  A Mortensen; E B Jensen; P B Petersen; S Husted; F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1979-04

4.  Measurement of rate of extravasation of plasma protein in inflammatory responses in guinea-pig skin using a continuous recording method.

Authors:  T J Williams; J Morley
Journal:  Br J Exp Pathol       Date:  1974-02

Review 5.  Clinical pharmacology of non-steroidal anti-inflammatory drugs.

Authors:  R O Day; G G Graham; K M Williams; G D Champion; J de Jager
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

6.  Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation.

Authors:  J J Lima; J J MacKichan; N Libertin; J Sabino
Journal:  J Pharmacokinet Biopharm       Date:  1983-10

7.  Synovial permeability in rheumatoid arthritis.

Authors:  P A Simkin
Journal:  Arthritis Rheum       Date:  1979-07

8.  Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events.

Authors:  H E Rugstad; O Hundal; I Holme; O B Herland; G Husby; K E Giercksky
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

9.  A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis.

Authors:  G Husby; I Holme; H E Rugstad; O B Herland; K E Giercksky
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

10.  Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies.

Authors:  D C Hobbs; T M Twomey
Journal:  J Clin Pharmacol       Date:  1979 May-Jun       Impact factor: 3.126

View more
  1 in total

1.  Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding?

Authors:  H A Wynne; A Long; E Nicholson; A Ward; D Keir
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.